Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain.
It is thought that the physiological actions of endogenous cannabinoid arachidonylethanolamide (AEA), as well as exogenous cannabinoids such as Delta9-tetrahydrocannabinol (THC), are mediated by two subtypes of cannabinoid receptors, CB1 and CB2, which have recently been characterized. Injection of AEA leads to alterations in motor behavior and endocrine function. While these phenomena have been well characterized, the neuronal substrate of AEA's actions remains undetermined. In this study, FOS immunoreactivity (FOSir) was used to map rat brain nuclei that are responsive to a single intracerebroventricular injection of AEA. The results showed that FOSir was induced in several nuclei including the bed nucleus of the stria terminalis (BNST), paraventricular nucleus of the hypothalamus (PVN), central nucleus of the amygdala (Ce), periaqueductal gray area (PAG), dentate gyrus in the hippocampus (Dg), paraventricular nucleus of the thalamus (PVA), median preoptic nucleus (MnPO), periventricular nucleus (Pe), caudate putamen (CPU) and the ependymal lining of the ventricles. The pattern of activation identified correlates, in part, with the distribution of CB receptors. At the same time, a new subset of nuclei, without demonstrable CB receptors, have been shown to respond to an AEA challenge. Activation of these nuclei is consistent with the physiological effects of AEA. These findings provide valuable information on the response to AEA at the level of neuronal activation and provide the basis for a broader understanding of the possible role of CB receptors in the modulation of motor and endocrine function associated with the use of exogenous cannabinoids, such as marijuana.
Patel
N A
NA
Department of Biology, Seton Hall University, 400 South Orange Avenue, South Orange, NJ 07079, USA.
Moldow
R L
RL
Patel
J A
JA
Wu
G
G
Chang
S L
SL
D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology*; D001923:Brain Chemistry / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002186:Cannabinoids / Q000494:pharmacology; D004027:Diencephalon / Q000737:chemistry; D063388:Endocannabinoids; D004805:Ependyma / Q000737:chemistry; D007150:Immunohistochemistry; D008297:Male; D008636:Mesencephalon / Q000737:chemistry; D053284:Polyunsaturated Alkamides; D016760:Proto-Oncogene Proteins c-fos / Q000032:analysis* / Q000276:immunology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists; D013687:Telencephalon / Q000737:chemistry; D013997:Time Factors
D001095:Arachidonic Acids; D002121:Calcium Channel Blockers; D002186:Cannabinoids; C469526:Cnr2 protein, rat; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D016760:Proto-Oncogene Proteins c-fos; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C078814:anandamide